The monoclonal antibody nirsevimab is capable of preventing RSV hospitalizations in 80% of cases where it is administered, but in Italy there have been regional discrepancies that have made prevention a geographic privilege. A national plan is needed that must address some specific program and organization points (as well as constant evaluation).
Marchetti, F., Cocchi, E. (2025). Efficacia di nirsevimab nella prevenzione del VRS: sfide e prospettive di equità. MEDICO E BAMBINO, 44(10), 619-620 [10.53126/meb44619].
Efficacia di nirsevimab nella prevenzione del VRS: sfide e prospettive di equità
Marchetti, Federico
;Cocchi, Enrico
2025
Abstract
The monoclonal antibody nirsevimab is capable of preventing RSV hospitalizations in 80% of cases where it is administered, but in Italy there have been regional discrepancies that have made prevention a geographic privilege. A national plan is needed that must address some specific program and organization points (as well as constant evaluation).File in questo prodotto:
Eventuali allegati, non sono esposti
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
